Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial-Reference-Cited by-同舟云学术

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Published:2017-06 Issue:6 Volume:18 Page:770-778
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Alistar Angela,Morris Bonny B,Desnoyer Rodwige,Klepin Heidi D,Hosseinzadeh Keyanoosh,Clark Clancy,Cameron Amy,Leyendecker John,D'Agostino Ralph,Topaloglu Umit,Boteju Lakmal W,Boteju Asela R,Shorr Rob,Zachar Zuzana,Bingham Paul M,Ahmed Tamjeed,Crane Sandrine,Shah Riddhishkumar,Migliano John J,Pardee Timothy S,Miller Lance,Hawkins Gregory,Jin Guangxu,Zhang Wei,Pasche Boris

Funder

Wake Forest Baptist Comprehensive Cancer Center's National Cancer Institute Cancer Center

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. SEER Cancer Statistics Review;Howlader,1975

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

4. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anti-cancer agents in vivo;Zachar;J Mol Med,2011

5. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process;Stuart;Cancer Metab,2014

Cited by 182 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging mechanisms and promising approaches in pancreatic cancer metabolism;Cell Death & Disease;2024-08-01

2. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study;Journal of Clinical Oncology;2024-08-01

3. Identification of 6-Fluorine-Substituted Coumarin Analogues as POLRMT Inhibitors with High Potency and Safety for Treatment of Pancreatic Cancer;Journal of Medicinal Chemistry;2024-07-25

4. Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumors;2024-07-25

5. Inhibition of pyruvate dehydrogenase accelerates anaerobic glycolysis under postmortem simulating conditions;Meat Science;2024-07